Acer Therapeutics (ACER)
(Delayed Data from OTC)
$0.66 USD
0.00 (0.00%)
Updated Nov 20, 2023 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Acer Therapeutics Inc. [ACER]
Reports for Purchase
Showing records 161 - 180 ( 213 total )
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Recap of 22 Expert Calls in 2018 - 2019 for Our Coverage Universe
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
1Q19 - All Eyes are Focused on June 25 - Must Read
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Join the Convo with Lead Author of Paris Registry Data
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Long-Awaited Patient Registry Data Set Published; EDSIVO Approval Decision Nears; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Fresh off the Press Publication Proves EDSIVO Improves Survival
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
2018 Financial Results Reported; Looking Ahead to EDSIVO Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Healthcare - Part 2 - Which Orphan Companies to See and Why at Our 31st ROTH Conference?
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Osanetant Licensing Transaction Bolsters Pipeline; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
EDSIVO May Enter the Market as Early as Summer 2019; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
EDSIVO Approval Approaching; Further Pipeline Initiatives; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Healthcare - Yas'' Weekly Recap - What the Buy Side Reads
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y